|
May 19, 2009 - . ("Neptune") (NASDAQ.NEPT -
TSX.V.NTB) today reports its consolidated financial results for the
fiscal year ended February 28, 2009. Neptune reports record revenues, EBITDA(1)
and first-time profitability for the three-month period ended February 28, 2009.
Neptune and Acasti Pharma amended their stock option plan.Financial Results:
Three-Month Period ended February 28, 2009 Sales Growth:
Revenues for the three-month period ended February 28, 2009 totalled a record
$3,772,000, a 31% increase compared to $2,875,000 for the three- month
period ended February 29, 2008.
About Neptune Technologies & Bioressources Inc.
Neptune is an industry-recognized leader in the innovation, production and
formulation of science-based and clinically-proven novel phospholipid products
for the nutraceutical and pharmaceutical markets. The Company focuses on growing
consumer health markets including cardiovascular, inflammatory and neurological
disease driven by consumers taking a more proactive approach to managing health
and preventing disease. The Company carries out clinical trials to show the
therapeutic benefits in various medical indications and to obtain regulatory
approved health claims. Neptune is continuously expanding on its portfolio of
intellectual property, clinical studies, regulatory approvals and health claims.
Neptune has its products marketed and distributed in over 20 countries
worldwide.
Contact:
Web Site:
http://www.neptunebiotech.com.
Source. |
